🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
1.000
+0.090 (9.89%)
Nov 19, 2026, 4:00 PM EST - Market closed

Aardvark Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-72.76-57.59-20.59-7.21-13.56
Depreciation & Amortization
0.040.040.02-0.11
Loss (Gain) From Sale of Investments
-0.33-1.30.121.222.32
Stock-Based Compensation
7.513.950.440.310.41
Provision & Write-off of Bad Debts
--0.120.760.49
Other Operating Activities
0.350.380.24-0.831
Change in Accounts Payable
-2.860.240.80.780.03
Change in Other Net Operating Assets
1.230.120.78-0.86-1.34
Operating Cash Flow
-66.81-54.17-18.09-5.82-10.54
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
--0.1-0.11--
Investment in Securities
87.3-49.57-11.89--
Other Investing Activities
-----1
Investing Cash Flow
87.3-49.67-12--1

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Issuance of Common Stock
0.5691.640.33-0.23
Other Financing Activities
--2.39-3.34--
Financing Cash Flow
0.5689.2581.99-0.23

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Cash Flow
21.05-14.5951.91-5.82-11.32

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-66.81-54.27-18.2-5.82-10.54
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-3.06-2.77-4.55-1.47-2.71
Levered Free Cash Flow
-48.08-31.18-10.67-3.54-
Unlevered Free Cash Flow
-48.08-31.18-10.67-3.54-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Change in Working Capital
-1.630.361.57-0.08-1.31
SEC Filings: 10-K · 10-Q